Corvus Pharmaceuticals, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Corvus Pharmaceuticals, Inc. (CRVS) had Operating Lease, Weighted Average Discount Rate, Percent of 11.70% as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 11.70%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 11.70%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 11.70%.
- 2025-06-30: Operating Lease, Weighted Average Discount Rate, Percent 11.70%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 11.70% 10-Q · filed 2026-08-06 |
| 2026-03-31 | 11.70% 10-Q · filed 2026-05-07 |
| 2025-09-30 | 11.70% 10-Q · filed 2025-11-04 |
| 2025-06-30 | 11.70% 10-Q · filed 2026-08-06 |
| 2025-03-31 | 11.70% 10-Q · filed 2026-05-07 |
| 2024-09-30 | 8.00% 10-Q · filed 2024-11-12 |
| 2024-06-30 | 8.00% 10-Q · filed 2024-08-06 |
| 2024-03-31 | 8.00% 10-Q · filed 2024-05-07 |
| 2023-12-31 | 8.00% 10-K · filed 2024-03-19 |
| 2023-09-30 | 8.00% 10-Q · filed 2024-11-12 |
| 2023-06-30 | 8.00% 10-Q · filed 2024-08-06 |
| 2023-03-31 | 8.00% 10-Q · filed 2024-05-07 |
| 2022-12-31 | 8.00% 10-K · filed 2024-03-19 |
| 2022-09-30 | 8.00% 10-Q · filed 2023-11-07 |
| 2022-06-30 | 8.00% 10-Q · filed 2023-08-08 |
| 2022-03-31 | 8.00% 10-Q · filed 2023-05-08 |
| 2021-12-31 | 8.00% 10-K · filed 2024-03-19 |
| 2021-09-30 | 8.00% 10-Q · filed 2022-11-03 |
| 2021-06-30 | 10.00% 10-Q · filed 2022-08-08 |
| 2021-03-31 | 10.00% 10-Q · filed 2022-05-05 |
| 2020-12-31 | 10.00% 10-K · filed 2023-03-28 |
| 2020-09-30 | 10.00% 10-Q · filed 2021-11-01 |
| 2020-06-30 | 10.00% 10-Q · filed 2021-08-02 |
| 2020-03-31 | 10.00% 10-Q · filed 2021-04-29 |
| 2019-12-31 | 10.00% 10-K · filed 2022-03-10 |
| 2019-09-30 | 10.00% 10-Q · filed 2020-10-29 |
| 2019-06-30 | 10.00% 10-Q · filed 2020-07-30 |
| 2019-03-31 | 10.00% 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |